An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Registrational
Sponsors Boehringer Ingelheim Pharmaceuticals

12 Jan 2022 final results particularly focus on patients enrolled in China published in the Targeted Oncology
10 Sep 2019 Results from the study along with LUX-Lung 3, 6, and 7 trials were presented at the 20th World Conference on Lung Cancer.
10 Sep 2019 Results of a pooled analysis of Asian phase IIIB trial and a German non-interventional study assessing the sensitivity of uncommon EGFR mutations to afatinib, presented at the 20th World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com